Bamlanivimab - Potential Risk Of Treatment Failure Due To Circulation Of Resistant Sars-cov-2 Variants

Bamlanivimab Recall Summary Bamlanivimab, a COVID-19 treatment medication, is being recalled across Canada because certain variants of the virus may not respond to this drug. The recall is being issued due to the emergence of SARS-CoV-2 variants that are resistant to bamlanivimab, which could make the treatment ineffective for some patients.

Reason

COVID - Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2021-04-28

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/49eecbeb-0e9f-42e0-b610-c1f1654ff1b9